{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:33:00Z","timestamp":1777858380332,"version":"3.51.4"},"reference-count":66,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Dept. of Veteran\u2019s Affairs CSR&D","award":["5I01CX000776-04"],"award-info":[{"award-number":["5I01CX000776-04"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is growing interest in developing pharmacological agents to reverse alcohol (ethanol) intoxication, akin to naloxone for opioids. GABAergic modulation offers a potential pathway for reversing alcohol effects, specifically by targeting extrasynaptic GABA-A receptors with a benzodiazepine partial inverse agonist. We tested the hypothesis that iomazenil, a benzodiazepine partial inverse agonist, can counteract alcohol intoxication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In a randomized, double-blind, placebo-controlled, within-subject design, healthy male volunteers (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200933) were administered intravenous alcohol (ethanol) or placebo, followed by intravenous iomazenil or placebo. Biphasic Alcohol Affects Scale, which assesses the stimulant and sedative effects of alcohol, was used as the primary outcome measure. For secondary measures, the Visual Analog Scale was used to assess \u201chigh,\u201d \u201cdrowsiness,\u201d \u201cBuzzed,\u201d and \u201canxiety.\u201d In addition, all subjects were asked to rate the number of standard alcohol drinks they believed had been administered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Alcohol produced greater sedation and stimulation when compared to placebo. Iomazenil produced the expected effect of increased anxiety compared to the placebo. However, Iomazenil did not attenuate the sedative or stimulatory effects of alcohol intoxication. Similarly, iomazenil did not significantly change feelings of \u201cHigh,\u201d \u201cDrowsy,\u201d \u201cAnxious,\u201d or \u201cBuzzed\u201d produced by alcohol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although GABA-A receptors are thought to mediate the subjective effects associated with ethanol intoxication, this study failed to demonstrate a significant attenuation of ethanol intoxication by the benzodiazepine partial inverse agonist, iomazenil. This study raises questions as to the role of particular GABA-A receptor subtypes in ethanol intoxication and the extent to which GABA-A receptor subtype function must be reduced to attenuate human ethanol intoxication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251330746","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T10:56:14Z","timestamp":1752749774000},"page":"715-725","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9080-0581","authenticated-orcid":false,"given":"Nirmal","family":"Singh","sequence":"first","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismene","family":"Petrakis","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"NIAAA Center for the Translational Neuroscience of Alcoholism,Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"NIAAA Center for the Translational Neuroscience of Alcoholism,Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Luddy","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H","family":"Krystal","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"NIAAA Center for the Translational Neuroscience of Alcoholism,Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak Cyril","family":"DSouza","sequence":"additional","affiliation":[{"name":"VA Connecticut Healthcare System, West Haven, CT, USA"},{"name":"Department of Psychiatry, Yale University, New Haven, CT, USA"},{"name":"NIAAA Center for the Translational Neuroscience of Alcoholism,Yale University, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.198"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.132"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6836278"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370040096031"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.10.014"},{"key":"e_1_3_3_7_1","first-page":"9","volume-title":"Iomazenil and other brain receptor tracers for SPECT","author":"Beer H","year":"1990","unstructured":"Beer H, Bl\u00e4uenstein P, Hasler P, et al. (1990a) Iomazenil: Pharmacological and animal data. Iomazenil and other brain receptor tracers for SPECT. Basel: Editiones Roche, pp. 9\u201329."},{"key":"e_1_3_3_8_1","first-page":"1007","article-title":"In vitro and in vivo evaluation of iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors","volume":"31","author":"Beer HF","year":"1990","unstructured":"Beer HF, Blauenstein PA, Hasler PH, et al. (1990b). In vitro and in vivo evaluation of iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 31: 1007\u20131014.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435277"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.10.008"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(18)30143-6"},{"key":"e_1_3_3_12_1","first-page":"463","article-title":"The partial inverse benzodiazepine agonist Ro 15-4513 antagonizes acute ethanol effects in mice and rats","volume":"86","author":"Bonetti E","year":"1985","unstructured":"Bonetti E, Burkard W, Gabl M, et al. (1985) The partial inverse benzodiazepine agonist Ro 15-4513 antagonizes acute ethanol effects in mice and rats. Br J Pharmacol 86: 463P.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_3_13_1","article-title":"An azido analogue of the benzodiazepine antagonist Ro 15-1788 (Ro 15-4513) behaves as a partial inverse benzodiazepine agonist","volume":"18","author":"Bonetti E","year":"1984","unstructured":"Bonetti E, Polc P, Pieri L (1984) An azido analogue of the benzodiazepine antagonist Ro 15-1788 (Ro 15-4513) behaves as a partial inverse benzodiazepine agonist. Neurosci Lett 18: S30.","journal-title":"Neurosci Lett"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(83)90113-2"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3340849"},{"key":"e_1_3_3_16_1","volume-title":"Nonparametric Analysis of Longitudinal Data in Factorial Experiments","author":"Brunner E","year":"2002","unstructured":"Brunner E, Domhof S, Langer F (2002) Nonparametric Analysis of Longitudinal Data in Factorial Experiments. Ann Arbor, MI: The University of Michigan."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2016.1202764"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433504"},{"key":"e_1_3_3_19_1","first-page":"79","article-title":"CMA demands lower legal blood-alcohol level","volume":"166","author":"CMA","year":"2002","unstructured":"CMA (2002) CMA demands lower legal blood-alcohol level. CMAJ 166: 79.","journal-title":"CMAJ"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.020"},{"key":"e_1_3_3_21_1","first-page":"1885","article-title":"Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice","volume":"11","author":"Dell\u2019Osso B","year":"2015","unstructured":"Dell\u2019Osso B, Albert U, Atti AR, et al. (2015) Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat 11: 1885\u20131909.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1982.tb04974.x"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90076-4"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781585622658"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(88)90263-8"},{"key":"e_1_3_3_26_1","first-page":"155","article-title":"Cellular and behavioral neurobiology of alcohol: Receptor-mediated neuronal processes","volume":"3","author":"Grant KA","year":"1995","unstructured":"Grant KA, Lovinger DM (1995) Cellular and behavioral neurobiology of alcohol: Receptor-mediated neuronal processes. Clin Neurosci 3: 155\u2013164.","journal-title":"Clin Neurosci"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1398"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.05.035"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1095-1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/290514a0"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13310.x"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92385-7"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90182-Q"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245334"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01380-2"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2002.tb02627.x"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.9.957"},{"key":"e_1_3_3_38_1","volume-title":"Psychopharmacology: A Fifth Generation of Progress","author":"Krystal JH","year":"2002","unstructured":"Krystal JH, Tabakoff B (2002) Ethanol abuse, dependence, and withdrawal: Neurobiology and clinical implications. In: Davis KL, Charney DS, Coyle JT, et al. (eds.) Psychopharmacology: A Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams and Wilkins."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2003.12.001"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067983"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067983"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198506000-00005"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1300\/J251v07n03_19"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1988.tb00243.x"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90366-9"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1993.tb00739.x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.04.044"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109102623"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.1.2"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.236"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.46"},{"key":"e_1_3_3_52_1","unstructured":"NIAAA Guidelines (2023) Available at: https:\/\/www.niaaa.nih.gov\/research\/guidelines-and-resources\/guidance_conducting_alcohol_administration_studies_human_participants"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.2.114"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113504017"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.08.008"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00498510"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.58"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntr258"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06356-0"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)24066-6"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.08.030185.000321"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.4161\/chan.4.6.12864"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2435171100"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(83)90286-2"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6223371"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1995.tb04374.x"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax4043"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251330746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251330746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251330746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:08Z","timestamp":1777507928000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251330746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/02698811251330746"],"URL":"https:\/\/doi.org\/10.1177\/02698811251330746","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}